CDKL5 and craniodiaphyseal dysplasia: We believe that future studies aimed at understanding the benefits of CoQ10-mediated blockade of oxidative stress in the Cdkl5-deficient brain will provide the rationale for the use of CoQ10 as supplemental therapy in CDD.